Human papillomavirus (HPV) and human immunodeficiency virus (HIV) infections are sexually transmitted. There are several HPV genotypes and clinical manifestations. Determining which genotypes circulate worldwide and/or in specific geographic areas can help with prevention programs and vaccine distribution. This systematic review aimed to investigate the most frequent anal and cervical HPV genotypes in women co-infected with HPV/HIV. The PubMed, Scientific Electronic Library Online, and Latin American and Caribbean Literature in Health Sciences databases were used to search for articles published between January 2015 and August 2021, and the included articles followed the defined selection criteria. Based on the 51 articles included, HPV16 was the most prevalent (41%) genotype, followed by HPV52 (17%) and HPV58 (14%). Based on the comparative analyses of the HIV-negative women with HPV and the HPV/HIV co-infected groups, HPV16 was frequent in both groups; HPV58, HPV31, and HPV52 were more frequent in the co-infected group; and HPV18 was more common in HIV-negative women with HPV. HPV/HIV co-infected women most frequently presented the HPV genotypes 16, 58, and 52, whereas HIV-negative women with HPV had a higher frequency of HPV16, HPV18, and HPV52 genotypes. The results indicate the importance of genotype surveillance as a strategy to improve preventive measures against HPV infection and its complications. International Prospective Register of Systematic Reviews (PROSPERO) registration number: CRD42020220121.
LucasSNelsonAM. HIV and the spectrum of human disease. J Pathol2015; 235(2): 229–241.
2.
Joint United Nations Programme on HIV/AIDS (UNAIDS). Aids by the numbers. https://www.unaids.org/en (accessed 9 November 2020).
3.
TovarJMBazalduaOVVargasL, et al.Human papillomavirus, cervical cancer, and the vaccines. Postgrad Med2008; 120(2): 79–84.
4.
NdizeyeZVanden BroeckDLebeloRL, et al.Prevalence and genotype-specific distribution of human papillomavirus in Burundi according to HIV status and urban or rural residence and its implications for control. PLoS One2019; 14(6): e0209303.
5.
MbulawaZZAvan SchalkwykCHuNC, et al.High human papillomavirus (HPV) prevalence in South African adolescents and young women encourages expanded HPV vaccination campaigns. PLoS One2018; 13(2): e0190166.
6.
WintherJFMøllerHTryggvadottirL, et al.Biological agents. APMIS1997; 105(Suppl 76): 120–131.
7.
MuñozNBoschFXde SanjoséS, et al.Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med2003; 348(6): 518–527.
8.
HalecGSchmittMDondogB, et al.Biological activity of probable/possible high-risk human papillomavirus types in cervical cancer. Int J Cancer2013; 132(1): 63–71.
HalecGAlemanyLLloverasB, et al.Pathogenic role of the eight probably/possibly carcinogenic HPV types 26, 53, 66, 67, 68, 70, 73 and 82 in cervical cancer. J Pathol2014; 234(4): 441–451.
ChakravartyJChourasiaAThakurM, et al.Prevalence of human papillomavirus infection & cervical abnormalities in HIV-positive women in eastern India. Indian J Med Res2016; 143(1): 79–86.
HancockGHellnerKDorrellL. Therapeutic HPV vaccines. Best Pract Res Clin Obstet Gynaecol2018; 47: 59–72.
15.
GerettiAMBrookGCameronC, et al.British HIV association guidelines on the use of vaccines in HIV-Positive adults 2015. HIV Med2016; 17(Suppl 3): s2–s81.
16.
EvelinBEmmilyIDóriaE, et al.Prevalência da coinfecção HIV-HPV em mulheres sororreagentes para HIV de Sergipe. Int Nursing Congress2017: 1–3.
17.
MenonSWusimanABoilyMC, et al.Epidemiology of HPV genotypes among HIV positive women in Kenya: a systematic review and meta-analysis. PLoS One2016; 11(10): e0163965.
18.
Boscolo-RizzoPFurlanCLupatoV, et al.Novel insights into epigenetic drivers of oropharyngeal squamous cell carcinoma: role of HPV and lifestyle factors. Clin Epigenetics2017; 9(1): 124.
19.
SweetKBosireCSanusiB, et al.Prevalence, incidence, and distribution of human papillomavirus types in female sex workers in Kenya. Int J STD AIDS2020; 31(2): 109–118.
20.
SignorelliCOdoneACiorbaV, et al.Human papillomavirus 9-valent vaccine for cancer prevention: a systematic review of the available evidence. Epidemiol Infect2017; 145(10): 1962–1982.
21.
de MartelCPlummerMVignatJ, et al.Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer2017; 141(4): 664–670.
22.
PRISMA. PRISMA–Transparent reporting of systematic reviews and meta-analyses. http://www.prisma-statement.org/ (accessed 20 August 2020).
McKenzieNDKobetzENHnatyszynJ, et al.Women with HIV are more commonly infected with non-16 and-18 high-risk HPV types. Gynecol Oncol2010; 116(3): 572–577.
27.
SossoSMTchouaketMCTFokamJ, et al.Human immunodeficiency virus is a driven factor of human papilloma virus among women: evidence from a cross-sectional analysis in Yaoundé, Cameroon. Virol J2020; 17(1): 69.
28.
MujuniFMiramboMMRambauP, et al.Variability of high risk HPV genotypes among HIV infected women in Mwanza, Tanzania-the need for evaluation of current vaccine effectiveness in developing countries. Infect Agent Cancer2016; 11(1): 49–57.
29.
AbelSNajioullahFVoluménieJL, et al.High prevalence of human papillomavirus infection in HIV-infected women living in French Antilles and French Guiana. PLoS One2019; 14(9): e0221334.
KrashiasGKoptidesDChristodoulouC. HPV prevalence and type distribution in Cypriot women with cervical cytological abnormalities. BMC Infect Dis2017; 17(1): 346.
32.
BruniLDiazMCastellsaguéX, et al.Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis2010; 202(12): 1789–1799.
33.
MuentesGDGGarcíaMAMGalárragaRIB, et al.Frequency and distribution of HPV genotypes in 800 genital samples of Ecuadorian men and women from the city of Guayaquil. Rev Inst Med Trop Sao Paulo2019; 61: e41.
34.
BatistaJESaddiVACarvalhoKPA, et al.Human papillomavirus genotypes 68 and 58 are the most prevalent genotypes in women from quilombo communities in the state of Maranhão, Brazil. Int J Infect Dis2017; 55: 51–55.
35.
do Desterro Soares Brandão NascimentoMVidalFCBda SilvaMACN, et al.Prevalence of human papillomavirus infection among women from quilombo communities in northeastern Brazil. BMC Womens Health2018; 18(1): 1.
CliffordGMTullySFranceschiS. Carcinogenicity of human papillomavirus (HPV) types in HIV-positive women: a meta-analysis from HPV infection to cervical cancer. Clin Infect Dis2017; 64(9): 1228–1235.
42.
GillesCBuljubasicMKonopnickiD, et al.Cervical, anal and oral human papillomavirus (HPV) infection in young women: a case control study between women with perinatally HIV infection and women with non-perinatally HIV infection. Eur J Obstet Gynecol Reprod Biol2020; 244: 114–119.
43.
ElliottTKohlerREMonareB, et al.Performance of vaginal self-sampling for human papillomavirus testing among women living with HIV in Botswana. Int J STD AIDS2019; 30(12): 1169–1176.
44.
CastilhoJLLeviJELuzPM, et al.A cross-sectional study of high-risk human papillomavirus clustering and cervical outcomes in HIV-infected women in Rio de Janeiro, Brazil. BMC Cancer2015; 15(1): 478.
45.
StricklerHDBurkRDFazzariM, et al.Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus-positive women. J Natl Cancer Inst2005; 97(8): 577–586.
46.
Federação Brasileira das Sociedades de Ginecologia e Obstetrícia. Papilomavírus humano (HPV): diagnóstico e tratamento. ProjetoDiretrizes2002; 1–19.
47.
TsakogiannisDGartzonikaCLevidiotou-StefanouS, et al.Molecular approaches for HPV genotyping and HPV-DNA physical status. Expert Rev Mol Med2017; 19: e1.
BurgerEAKimJJSyS, et al.Age of acquiring causal human papillomavirus (HPV) infections: leveraging simulation models to explore the natural history of HPV-induced cervical cancer. Clin Infect Dis2017; 65(6): 893–899.
50.
OrlandoGFratiERFasoloMM, et al.Incident genital HPV infections and potential impact of HPV vaccines in adult women living with HIV/AIDS. Hum Vaccin Immunother2019; 15(7–8): 1904–1910.
51.
HuhWKJouraEAGiulianoAR, et al.Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial. Lancet2017; 390(10108): 2143–2159.
52.
JouraEAGiulianoARIversenOE, et al.A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med2015; 372(8): 711–723.
53.
YarDDSalifuSPDarkoSN, et al.Genotypic characterisation of human papillomavirus infections among persons living with HIV infection; a case-control study in Kumasi, Ghana. Trop Med Int Health2015; 21(2): 275–282.
54.
CambouMCLeviJELakeJE, et al.Time trend analysis of cervical high-risk human papillomavirus (HPV) in HIV-infected women in an urban cohort from Rio de Janeiro, Brazil: the rise of non-16/18 HPV. Int J Infect Dis2015; 41: 17–20.
55.
TayibSAllanBWilliamsonAL, et al.Human papillomavirus genotypes and clinical management of genital warts in women attending a colposcopy clinic in Cape Town, South Africa. South African Med J2015; 105(8): 679–684.
56.
MenezesLJPoongulaliSTommasinoM, et al.Prevalence and concordance of human papillomavirus infection at multiple anatomic sites among HIV-infected women from Chennai, India. Int J STD AIDS2016; 27(7): 543–553.
57.
KonopnickiDManigartYGillesC, et al.High-risk human papillomavirus genotypes distribution in a cohort of HIV-positive women living in Europe: epidemiological implication for vaccination against human papillomavirus. Aids2016; 30(3): 425–433.
58.
ThorsteinssonKStorgaardMKatzensteinTL, et al.Prevalence and distribution of cervical high-risk human papillomavirus and cytological abnormalities in women living with HIV in Denmark–the SHADE. BMC Cancer2016; 16(1): 866.
59.
MenonSRossiRBenoyI, et al.Human papilloma virus infection in HIV-infected women in Belgium: implications for prophylactic vaccines within this subpopulation. Eur J Cancer Prev2016; 27(1): 46–53.
60.
ThungaSAndrewsARamapuramJ, et al.Cervical cytological abnormalities and human papilloma virus infection in women infected with HIV in Southern India. J Obstet Gynaecol Res2016; 42(12): 1822–1828.
61.
De PokomandyAKaufmanEDe CastroC, et al.The EVVA cohort study: Anal and cervical type-specific human papillomavirus prevalence, persistence, and cytologic findings in women living with HIV. J Infect Dis2017; 216(4): 447–456.
62.
MirandaAESilveiraMFTravassosAG, et al.High-risk papillomavirus infection among women living with human Immunodeficiency virus: Brazilian multicentric study. J Med Virol2017; 89(12): 2217–2223.
63.
ManeASahasrabuddheVVNirmalkarA, et al.Rates and determinants of incidence and clearance of cervical HPV genotypes among HIV-seropositive women in Pune, India. J Clin Virol2017; 88: 26–32.
64.
KostBPHofmannJStoellnbergerS, et al.Prevalence of human papillomavirus infection of the anal canal in women: a prospective analysis of high-risk populations. Oncol Lett2017; 13(4): 2495–2501.
65.
Obiri-YeboahDAkakpoPKMutocheluhM, et al.Epidemiology of cervical human papillomavirus (HPV) infection and squamous intraepithelial lesions (SIL) among a cohort of HIV-infected and uninfected Ghanaian women. BMC Cancer2017; 17(1): 688.
66.
TartagliaEFalascaKVecchietJ, et al.Prevalence of HPV infection among HIV-positive and HIV-negative women in central/eastern Italy: strategies of prevention. Oncol Lett2017; 14(6): 7629–7635.
67.
OrlandoGBianchiSFasoloMM, et al.Cervical Human Papillomavirus genotypes in HIV-infected women: a cross-sectional analysis of the VALHIDATE study. J Prev Med Hyg2017; 58(4): E259–E265.
68.
KellyHANgouJChikandiwaA, et al.Associations of Human Papillomavirus (HPV) genotypes with high-grade cervical neoplasia (CIN2+) in a cohort of women living with HIV in Burkina Faso and South Africa. PLoS One2017; 12(3): e0174117.
69.
MbathaJNTaylorMKleppaE, et al.High-risk human papillomavirus types in HIV-infected and HIV-uninfected young women in KwaZulu-Natal, South Africa: implications for vaccination. Infect Dis (Lond)2017; 49(8): 601–608.
70.
VolpiniLPBBoldriniNATDe FreitasLB, et al.The high prevalence of HPV and HPV16 European variants in cervical and anal samples of HIV-seropositive women with normal Pap test results. PLoS One2017; 12(4): e0176422.
71.
MitchellSMPedersenHNEng StimeE, et al.Self-collection based HPV testing for cervical cancer screening among women living with HIV in Uganda: a descriptive analysis of knowledge, intentions to screen and factors associated with HPV positivity. BMC Womens Health2017; 17(1): 4.
72.
ChikandiwaAKellyHSawadogoB, et al.Prevalence, incidence and correlates of low risk HPV infection and anogenital warts in a cohort of women living with HIV in Burkina Faso and South Africa. PLoS One2018; 13(5): e0196018.
73.
OuladlahsenAFaysselNBensghirR, et al.The Human papillomavirus among women living with Human Immunodeficiency Virus in Morocco: a prospective cross-sectional study. J Infect Dev Ctries2018; 12(6): 477–484.
74.
KellyHFaustHChikandiwaA, et al.human papillomavirus serology among women living with HIV: type-specific seroprevalence, seroconversion, and risk of cervical reinfection. J Infect Dis2018; 218(6): 927–936.
75.
RodriguesLLSMorgadoMGSahasrabuddheVV, et al.Cervico-vaginal self-collection in HIV-infected and uninfected women from Tapajós region, Amazon, Brazil: high acceptability, hrHPV diversity and risk factors. Gynecol Oncol2018; 151(1): 102–110.
76.
TeixeiraMFSabidóMLeturiondoAL, et al.High risk human papillomavirus prevalence and genotype distribution among women infected with HIV in Manaus, Amazonas. Virol J2018; 15(1): 36.
77.
BadialRMDIasMCStuquiB, et al.Detection and genotyping of human papillomavirus (HPV) in HIV-infected women and its relationship with HPV/HIV co-infection. Medicine (Baltimore)2018; 97(14): e9545.
78.
MenonSLuchtersSRossiR, et al.Human papilloma virus correlates of high grade cervical dysplasia in HIV-infected women in Mombasa, Kenya: a cross-sectional analysis. Virol J2018; 15(1): 54.
79.
MudiniWPalefskyJMHaleMJ, et al.Human papillomavirus genotypes in invasive cervical carcinoma in HIV-Seropositive and HIV-Seronegative women in zimbabwe. J Acquir Immune Defic Syndr2018; 79(1): e1–e6.
80.
ErmelATonuiPTitusM, et al.A cross-sectional analysis of factors associated with detection of oncogenic human papillomavirus in human immunodeficiency virus-infected and uninfected Kenyan women. BMC Infect Dis2019; 19(1): 352.
81.
ThorsteinssonKLadelundSStorgaardM, et al.Persistence of cervical high-risk human papillomavirus in women living with HIV in Denmark–the SHADE. BMC Infect Dis2019; 19(1): 740.
82.
ManyereNRDube MandishoraRSMagwaliT, et al.Human papillomavirus genotype distribution in genital warts among women in Harare-Zimbabwe. J Obstet Gynaecol2019; 40(6): 830–836.
83.
MaremboTDube MandishoraRBorokM. Use of multiplex polymerase chain reaction for detection of high-risk human papillomavirus genotypes in women attending routine cervical cancer screening in harare. Intervirology2019; 62(2): 90–95.
84.
NyasenuYTGbeasor-KomlanviFAEhlanA, et al.Prevalence and distribution of Human Papillomavirus (HPV) genotypes among HIV infected women in Lomé, Togo. PLoS One2019; 14(2): e0212516.
85.
TaweLMacduffieENarasimhamurthyM, et al.Human papillomavirus genotypes in women with invasive cervical cancer with and without human immunodeficiency virus infection in Botswana. Int J Cancer2020; 146(6): 1667–1673.
86.
KaraniLWMusyokiSOrinaR, et al.Human papillomavirus genotype profiles and cytological grades interlinkages in coinfection with HIV. Pan Afr Med J2020; 35: 67.
87.
AdedimejiARogersADzudieA, et al.Cervical human papillomavirus DNA detection in women living with HIV and HIV-uninfected women living in Limbe, Cameroon. J Clin Virol2020; 128: 104445.
88.
ThistlePParpiaRPainD, et al.Prevalence and subtype distribution of high-risk human papillomavirus among women presenting for cervical cancer screening at karanda mission hospital. JCO Glob Oncol2020; 6(6): 1276–1281.
89.
GuthrieBLRositchAFCooperJA, et al.Human papillomavirus and abnormal cervical lesions among HIV-infected women in HIV-discordant couples from Kenya. Sex Transm Infect2020; 96(6): 457–463.
90.
JohnsonLGSaiduRMbulawaZ, et al.Selecting human papillomavirus genotypes to optimize the performance of screening tests among South African women. Cancer Med2020; 9(18): 6813–6824.
91.
AdebamowoSNAdeyemoAARotimiCN, et al.Genome-wide association study of prevalent and persistent cervical high-risk human papillomavirus (HPV) infection. BMC Med Genet2020; 21(1): 231.
92.
MurenziGTuyisengePKanyabwishaF, et al.Type-specific persistence, clearance and incidence of high-risk HPV among screen-positive Rwandan women living with HIV. Infect Agent Cancer2021; 16(1): 16–19.
93.
MonteiroJCFonsecaRRdSFerreiraTCdS, et al.Prevalence of high risk HPV in HIV-Infected women from Belém, Pará, Amazon region of Brazil: a cross-sectional study. Front Public Heal2021; 9: 1–8.
94.
Dube MandishoraRSRoungeTBFitzpatrickM, et al.Self-collected and clinician-collected anal swabs show modest agreement for HPV genotyping. PLoS One2021; 16(4): 1–13.
95.
IsaguliantsMNosikMKarlsenA, et al.Prevalence and risk factors of infection with high risk human papilloma viruses among hiv-positive women with clinical manifestations of tuberculosis in a middle-income country. Biomedicines2021; 9(6): 683.
96.
DuanRZhangHWuA, et al.Prevalence and risk factors for anogenital HPV infection and neoplasia among women living with HIV in China. Sex Transm Infect2021; 2: 1–8.
97.
DubTCœurSLNgo-Giang-HuongN, et al.Prevalence of high-risk human papillomavirus infections before and after cervical lesion treatment, among women living with HIV. J Clin Med2021; 10(14): 3133.
98.
Tagne SimoRKiafonFBNangueC, et al.Influence of HIV infection on the distribution of high-risk HPV types among women with cervical precancerous lesions in Yaounde, Cameroon. Int J Infect Dis2021; 110: 426–432.
99.
ErmelATongYTonuiP, et al.Longer duration of anti-retroviral therapy is associated with decreased risk of human papillomaviruses detection in Kenyan women living with HIV. Int J STD AIDS2021; 32(13):1212–1220.
